全文获取类型
| 收费全文 | 31061篇 |
| 免费 | 2782篇 |
| 国内免费 | 1304篇 |
学科分类
| 医药卫生 | 35147篇 |
出版年
| 2023年 | 389篇 |
| 2022年 | 463篇 |
| 2021年 | 1173篇 |
| 2020年 | 1028篇 |
| 2019年 | 962篇 |
| 2018年 | 1085篇 |
| 2017年 | 953篇 |
| 2016年 | 956篇 |
| 2015年 | 1247篇 |
| 2014年 | 1550篇 |
| 2013年 | 1490篇 |
| 2012年 | 2304篇 |
| 2011年 | 2345篇 |
| 2010年 | 1341篇 |
| 2009年 | 1124篇 |
| 2008年 | 1657篇 |
| 2007年 | 1687篇 |
| 2006年 | 1646篇 |
| 2005年 | 1649篇 |
| 2004年 | 1201篇 |
| 2003年 | 1025篇 |
| 2002年 | 915篇 |
| 2001年 | 775篇 |
| 2000年 | 789篇 |
| 1999年 | 759篇 |
| 1998年 | 427篇 |
| 1997年 | 353篇 |
| 1996年 | 277篇 |
| 1995年 | 303篇 |
| 1994年 | 236篇 |
| 1993年 | 174篇 |
| 1992年 | 302篇 |
| 1991年 | 292篇 |
| 1990年 | 274篇 |
| 1989年 | 256篇 |
| 1988年 | 216篇 |
| 1987年 | 202篇 |
| 1986年 | 197篇 |
| 1985年 | 151篇 |
| 1984年 | 103篇 |
| 1983年 | 70篇 |
| 1982年 | 44篇 |
| 1981年 | 51篇 |
| 1980年 | 42篇 |
| 1979年 | 72篇 |
| 1978年 | 51篇 |
| 1977年 | 52篇 |
| 1974年 | 65篇 |
| 1973年 | 60篇 |
| 1972年 | 63篇 |
排序方式： 共有10000条查询结果，搜索用时 15 毫秒
1.
2.
3.
4.
5.
7.
肝细胞癌(HCC)是最常见的恶性肿瘤之一。尽管在早期诊断和个体化治疗方面取得了进展,但经根治性切除等治疗后,HCC患者的临床预后仍不佳,复发率高。因此,在HCC患者中识别准确可靠的预后标志物是必要的。作为一种新的免疫营养生物标志物,控制营养状态(CONUT)评分已被报道用于预测癌症患者的预后。本文将对术前CONUT评分与HCC肝切除术后预后的研究进展进行综述。 相似文献
8.
9.
Inna Y. Gong Nigel S. Tan Sammy H. Ali Gerald Lebovic Muhammad Mamdani Shaun G. Goodman Dennis T. Ko Andreas Laupacis Andrew T. Yan 《The Canadian journal of cardiology》2019,35(5):653-660
Background
Although it is known that women do not participate in trials as frequently as men, there are limited recent data examining how women recruitment has changed over time.Methods
We conducted MEDLINE search using a validated strategy for randomized trials published in New England Journal of Medicine, Lancet, and Journal of the American Medical Association between 1986 and 2015, and included trials evaluating pharmacologic or nonpharmacologic therapies. We abstracted data on demographics, intervention type, clinical indication, and trial design characteristics, and examined their relationships with women enrollment.Results
In total, 598 trials met inclusion criteria. Women enrollment increased significantly over time (21% between 1986 and 1990 to 33% between 2011 and 2015; Pfor trend < 0.001) and did not differ by journal or funding source. Women enrollment varied with clinical indication, comprising 37% for non–coronary artery disease vascular trials, 30% for coronary artery disease trials, 28% for heart failure trials, and 28% for arrhythmia trials (P < 0.001), which were all significantly lower than the expected proportion in disease populations (P < 0.001). Women enrollment varied with trial type (31%, 29%, and 26% for pharmacologic, device, and procedural trials, respectively; P = 0.001). These findings were corroborated using multivariable analysis. We found significant positive correlations between women enrolled, and mean age and total number of participants. Fewer women were enrolled in trials reporting statistically significant results than those who did not (P = 0.001).Conclusions
Although enrollment of women has increased over time, it remains lower than the relative proportion in the disease population. Future studies should elucidate the reasons for persistent under-representation of women in clinical trials. 相似文献10.
